A Comparative Economic Analysis of Immunization Programs for Pertussis and Measles: The Use of ARIMA Model to Study the Epidemiological Situation in England and Wales
DOI:
https://doi.org/10.6000/1929-6029.2013.02.03.1Keywords:
Pertussis and measles immunization, cost analysis of vaccination program, epidemiology of pertussis and measles in England and Wales, ARIMA transfer function modelAbstract
Objective: We evaluate pertussis and measles immunization strategies and compare the consequences in terms of health effects and economic costs.
Methods: Based on epidemiological data for pertussis and measles in England and Wales from 1970 to 2012, we use ARIMA approach to model the relation between notification cases and vaccination coverage for each disease. We then perform an economic evaluation of vaccination programs at 95% and discuss the benefits for the society to achieve this level when compared with lower vaccination rates currently observed. The advantages for the society of increasing vaccination coverage up to 98% are considered respectively for pertussis and measles.
Results: The programs at a 95% vaccination rate, which is able to significantly reduce the mortality and the morbidity due to pertussis and measles, are confirmed to be the best cost saving immunization strategy. The total social net benefits are systematically maximized when the programs are compared to strategies with lower vaccination coverage. The decision to exceed the herd immunity level and reach the rate at 98% is economically justified for measles, while for pertussis the programs at 98% are less cost effective than the programs at 95%.
Conclusion: Additional efforts must be carried out to promote measles vaccination since immunization strategies at 95% and at higher rates are recommended on epidemiological and economic grounds.
References
Kremer JR, Muller CP. Measles in Europe - there is room for improvement. Lancet 2009; 373(9661): 356-8. http://dx.doi.org/10.1016/S0140-6736(08)61850-4 DOI: https://doi.org/10.1016/S0140-6736(08)61850-4
ECDC European Centre for Disease Prevention and Control: Number of measles cases 2012.
CDC Centers for Disease Control and Prevention: Measles-United States 2011. MMWR 2012; 61(15), 253-7. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6115a1.htm?s_cid=mm6115a1_w
Girard DZ. Intervention time series analysis of pertussis vaccination in England and Wales. Health Policy 2000; 54: 13-25. http://dx.doi.org/10.1016/S0168-8510(00)00096-8 DOI: https://doi.org/10.1016/S0168-8510(00)00096-8
CDC Centers for Disease Control and Prevention: Summary of Notifiable Diseases-United States 2010. MMWR June 1, 2012; 59(53).
http://www.cdc.gov/mmwr/PDF/wk/mm5953. pdf
World Health Organization. Immunization surveillance, assessment and monitoring.
http://www.who.int/immunization_monitoring/data/incidence_series.xls
ECDC European Centre for Disease Prevention and Control. Annual epidemiological report Reporting on 2010 surveillance data and 2011 epidemic intelligence data 2012. http://ecdc.europa.eu/en/publications/publications/annual-epidemiological-report-2012.pdf
Fine PEM. Herd-Immunity - History, Theory, Practice. Epidemiol Rev 1993; 15: 265-302. DOI: https://doi.org/10.1093/oxfordjournals.epirev.a036121
Moss WJ, Griffin DE. Measles. Lancet 2012; 379: 153-64. http://dx.doi.org/10.1016/S0140-6736(10)62352-5 DOI: https://doi.org/10.1016/S0140-6736(10)62352-5
Smith A, Yarwood J, Salisbury, DM. Tracking mothers' attitudes to MMR immunisation 1996-2006. Vaccine 2007; 25: 3996-4002. http://dx.doi.org/10.1016/j.vaccine.2007.02.071 DOI: https://doi.org/10.1016/j.vaccine.2007.02.071
Downs JS, de Bruin WB, Fischhoff B. Parents' vaccination comprehension and decisions. Vaccine 2008; 26: 1595-607. http://dx.doi.org/10.1016/j.vaccine.2008.01.011 DOI: https://doi.org/10.1016/j.vaccine.2008.01.011
Baker JP. The pertussis vaccine controversy in Great Britain, 1974-1986. Vaccine 2003; 21: 4003-10. http://dx.doi.org/10.1016/S0264-410X(03)00302-5 DOI: https://doi.org/10.1016/S0264-410X(03)00302-5
Anderberg D, Chevalier A, Wadsworth J. Anatomy of a health scare: Education, income and the MMR controversy in the UK. J Health Econ 2011; 30: 515-30. http://dx.doi.org/10.1016/j.jhealeco.2011.01.009 DOI: https://doi.org/10.1016/j.jhealeco.2011.01.009
CDC Center for Disease Control and Prevention. Pertussis - United States, January 1992-June. MMWR 1995; 44(28): 525-9.
Black S. Epidemiology of pertussis. Pediatr Infect Dis J 1997; 16: S85-9. http://dx.doi.org/10.1097/00006454-199704001-00003 DOI: https://doi.org/10.1097/00006454-199704001-00003
Stevenson M, Beard S, Finn A, Brennan A. Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule. Vaccine 2002; 20: 1778-86. http://dx.doi.org/10.1016/S0264-410X(02)00025-7 DOI: https://doi.org/10.1016/S0264-410X(02)00025-7
Vitek CR, Pascual FR, Baugham AT, Murphy TV. Increase in deaths from pertussis from young infants in the United States in the 1990s. Pediatr Infect Dis J 2003; 22: 628-34. http://dx.doi.org/10.1097/01.inf.0000073266.30728.0e DOI: https://doi.org/10.1097/01.inf.0000073266.30728.0e
Beutels Ph, Bonanni P, Tormans G, Canale F, Crovari PC. An economic evaluation of universal pertussis vaccination in Italy. Vaccine 1999; 17(19): 2400-9. http://dx.doi.org/10.1016/S0264-410X(99)00028-6 DOI: https://doi.org/10.1016/S0264-410X(99)00028-6
Gustafsson L, Hollander HO, Olin P, Reizenstein PE, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New Engl J Med 1996; 334(6): 349-56. http://dx.doi.org/10.1056/NEJM199602083340602 DOI: https://doi.org/10.1056/NEJM199602083340602
Miller E, Waight P, Laurichesse H, Andrews N, Thorneton C, Sesardic D, Corbel M. Immunogenicity and reactogenicity of acellular diphtheria/tetanus/pertussis vaccines given as a pre-school booster. Effect of simultaneous administration of MMR. Vaccine 2001; 19: 3904-11. http://dx.doi.org/10.1016/S0264-410X(01)00123-2 DOI: https://doi.org/10.1016/S0264-410X(01)00123-2
Nolan TF, Goodman RA, Patriarca PA, Hinman AR. Hospitalization for measles, 1970-78. Am J Public Health 1982; 72(9): 1037-9. http://dx.doi.org/10.2105/AJPH.72.9.1037 DOI: https://doi.org/10.2105/AJPH.72.9.1037
Filia A, Brenna A, Panà A, Cavallaro MG, Massari M, Ciofi degli Atti ML. Health burden and economic impact of measles-related hospitalizations in Italy in 2002-2003. BMC Public Health 2007; 7: 169. http://dx.doi.org/10.1186/1471-2458-7-169 DOI: https://doi.org/10.1186/1471-2458-7-169
Ciofi degli Atti ML, Filia A, Massari M, Pizzuti R, Nicoletti L, D’argenzo A, et al. Assessment of measles incidence, measles-related complications and hospitalisations during an outbreak in a southern Italian region. Vaccine 2006; 24(9): 1332-8. http://dx.doi.org/10.1016/j.vaccine.2005.09.031 DOI: https://doi.org/10.1016/j.vaccine.2005.09.031
Carabin H, Edmunds WJ, Kou U, van den Hof S, Nguyen VH. The average cost of measles cases and adverse events following vaccination in industrialised countries. BMC Public Health 2002; 2: 22. http://dx.doi.org/10.1186/1471-2458-2-22 DOI: https://doi.org/10.1186/1471-2458-2-22
ARS. Regional Health Agencies (Agences Régionales de Santé).
http://www.sante.gouv.fr/agence-regionale-de-sante-ars.html
APIMA Association of Medical information. Vaccines, Age and Prices 2010.
http://www.apima.org/img_bronner/ Tableau_vaccins.pdf
HMRC HM Revenue & Customs 2011.
http://www.hmrc.gov. uk/paye/payroll/day-to-day/nmw.htm#4
Viscusi WK, Aldy JE. The value of a statistical life: A critical review of market estimates throughout the world. J Risk Uncertainty 2003; 27: 5-76. http://dx.doi.org/10.1023/A:1025598106257 DOI: https://doi.org/10.3386/w9487
EPA Environmental Protection Agency. Value of Statistical Life Analysis and Environmental Policy: A White Paper for presentation to Science Advisory Board - Environmental Economics Advisory Committee 2004.
http://yosemite.epa.gov/ee/epa/eerm.nsf/vwAN/EE-0483-01.pdf
Girard DZ. Recommended or mandatory pertussis vaccination policy in developed countries: Does the choice matter? Public Health 2012; 126(2): 117-22. http://dx.doi.org/10.1016/j.puhe.2011.11.007 DOI: https://doi.org/10.1016/j.puhe.2011.11.007
Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: The impact of herd-immunity. Med Decis Making 2003; 23: 76-82. DOI: https://doi.org/10.1177/0272989X02239651
Girard DZ. The distribution over time of costs and social net benefits for pertussis immunization programs. Int J Health care Finance Econ 2010; 10(1): 1-27. http://dx.doi.org/10.1007/s10754-009-9058-2 DOI: https://doi.org/10.1007/s10754-009-9058-2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2013 Dorota Zdanowska Girard
This work is licensed under a Creative Commons Attribution 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
